{
    "info": {
        "nct_id": "NCT04797884",
        "official_title": "A Randomized Study of Intrabucally Administered Electromagnetic Fields Versus Placebo for Patients With Child-Pugh A or B With Advanced Hepatocellular Carcinoma",
        "inclusion_criteria": "Biopsy-proven HCC that is locally advanced or metastatic OR\n\n* Patients without biopsy confirmation are also eligible if they meet one of the following criteria:\n\n  1. Radiologic diagnosis of HCC as per the AASLD guidelines OR\n  2. Liver cirrhosis AND a liver mass that shows arterial phase hyperenhancement on triphasic computed tomography (CT) or MRI, AND either:\n\n     * Is ≥ 20 mm with either non-peripheral portal washout or an enhancing capsule OR\n     * Is 10-19 mm with non-peripheral portal venous washout AND an enhancing capsule\n* For Child-Pugh A participants: treatment failure (defined as documented radiological progression) and/or intolerance to at least two prior treatments with approved or experimental systemic therapies including atezolizumab plus bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, ramucirumab, nivolumab, nivolumab plus ipilimumab, pembrolizumab or any other approved or experimental first line and/or second line therapy.\n* Child-Pugh B participants are not required to have received any prior treatment.\n* Measurable disease according to RECIST v 1.1.\n* At least one target lesion that has not previously received any local therapy, such as surgery, radiation therapy, hepatic arterial embolization, transarterial chemoembolization (TACE), hepatic arterial infusion, radio-frequency ablation, percutaneous ethanol injection or cryoablation, unless it has subsequently progressed by 20% or more according to RECIST v 1.1 and mRECIST for HCC.\n* Patients with Child-Pugh A or B (at time of enrollment) as defined by the parameters contained in the Child-Pugh Calculator. Subjects with Child-Pugh score of B8-B9 may be included if they have:\n\n  * Albumin ≥ 2.8 mg/l AND\n  * Total Bilirubin ≤ 3.0mg/l.\n* ECOG performance status of 0-2.\n* At least 2 weeks must have elapsed since administration of any anticancer treatment prior to initiation of protocol therapy.\n* Patients must be greater than or equal to 18 years old and must be able to understand and sign an informed consent.\n* Female patients of childbearing potential and their partners and male patients must agree to use adequate contraception during the period of study treatment.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Known leptomeningeal disease. (Previously treated, asymptomatic central nervous system (CNS) metastases are eligible).\n* Fibrolamellar HCC or combined hepatocellular-cholangiocarcinoma (cHCC-CC).\n* Prior treatment with the TheraBionic Device.\n* Patients with any of the following within the 12 months prior to registration: uncontrolled/unstable angina, myocardial infarction, coronary artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, including transient ischemic attack, or pulmonary embolism.\n* Pregnant or breastfeeding women.\n* Patients with another active malignancy within the past one year except for treated cervical cancer in situ, treated in situ carcinoma of the bladder or treated non-melanoma carcinoma of the skin, low-risk prostate cancer not requiring active treatment, treated T1/T2 glottic cancer, treated stage 0 or stage I breast cancer not requiring adjuvant therapy or treated non-invasive bladder cancer.\n* Patients receiving calcium channel blockers and any agent blocking L-type of T-type Voltage Gated Calcium Channels, e.g., amlodipine, nifedipine, ethosuximide, ascorbic acid (vitamin C), etc. unless their medical treatment is modified to exclude calcium channel blockers prior to enrollment.\n* Patients with curative treatment options available, including surgery or radiofrequency ablation, as assessed by their physician.\n* Patients receiving other anticancer treatments.\n* Patients that do not agree to be followed according to the study protocol.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* At least 2 weeks must have elapsed since administration of any anticancer treatment prior to initiation of protocol therapy.",
            "criterions": [
                {
                    "exact_snippets": "At least 2 weeks must have elapsed since administration of any anticancer treatment prior to initiation of protocol therapy.",
                    "criterion": "time since last anticancer treatment",
                    "requirements": [
                        {
                            "requirement_type": "elapsed time",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status of 0-2.",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be greater than or equal to 18 years old and must be able to understand and sign an informed consent.",
            "criterions": [
                {
                    "exact_snippets": "greater than or equal to 18 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must be able to understand and sign an informed consent",
                    "criterion": "informed consent capacity",
                    "requirements": [
                        {
                            "requirement_type": "ability to understand and sign informed consent",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease according to RECIST v 1.1.",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease according to RECIST v 1.1.",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST v 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total Bilirubin ≤ 3.0mg/l.",
            "criterions": [
                {
                    "exact_snippets": "Total Bilirubin ≤ 3.0mg/l.",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "mg/l"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Child-Pugh B participants are not required to have received any prior treatment.",
            "criterions": [
                {
                    "exact_snippets": "Child-Pugh B participants",
                    "criterion": "Child-Pugh classification",
                    "requirements": [
                        {
                            "requirement_type": "classification",
                            "expected_value": "B"
                        }
                    ]
                },
                {
                    "exact_snippets": "not required to have received any prior treatment",
                    "criterion": "prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of prior treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients without biopsy confirmation are also eligible if they meet one of the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "Patients without biopsy confirmation",
                    "criterion": "biopsy confirmation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is 10-19 mm with non-peripheral portal venous washout AND an enhancing capsule",
            "criterions": [
                {
                    "exact_snippets": "Is 10-19 mm",
                    "criterion": "lesion size",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 10,
                                        "unit": "mm"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 19,
                                        "unit": "mm"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "non-peripheral portal venous washout",
                    "criterion": "portal venous washout",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": "non-peripheral"
                        }
                    ]
                },
                {
                    "exact_snippets": "an enhancing capsule",
                    "criterion": "enhancing capsule",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Liver cirrhosis AND a liver mass that shows arterial phase hyperenhancement on triphasic computed tomography (CT) or MRI, AND either:",
            "criterions": [
                {
                    "exact_snippets": "Liver cirrhosis",
                    "criterion": "liver cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "a liver mass that shows arterial phase hyperenhancement on triphasic computed tomography (CT) or MRI",
                    "criterion": "liver mass arterial phase hyperenhancement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "imaging modality",
                            "expected_value": [
                                "triphasic computed tomography (CT)",
                                "MRI"
                            ]
                        },
                        {
                            "requirement_type": "arterial phase hyperenhancement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For Child-Pugh A participants: treatment failure (defined as documented radiological progression) and/or intolerance to at least two prior treatments with approved or experimental systemic therapies including atezolizumab plus bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, ramucirumab, nivolumab, nivolumab plus ipilimumab, pembrolizumab or any other approved or experimental first line and/or second line therapy.",
            "criterions": [
                {
                    "exact_snippets": "For Child-Pugh A participants",
                    "criterion": "Child-Pugh class",
                    "requirements": [
                        {
                            "requirement_type": "classification",
                            "expected_value": "A"
                        }
                    ]
                },
                {
                    "exact_snippets": "treatment failure (defined as documented radiological progression) and/or intolerance to at least two prior treatments",
                    "criterion": "treatment history",
                    "requirements": [
                        {
                            "requirement_type": "failure or intolerance to prior treatments",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "prior systemic therapies"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "including atezolizumab plus bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, ramucirumab, nivolumab, nivolumab plus ipilimumab, pembrolizumab or any other approved or experimental first line and/or second line therapy",
                    "criterion": "prior systemic therapies received",
                    "requirements": [
                        {
                            "requirement_type": "types of therapies",
                            "expected_value": [
                                "atezolizumab plus bevacizumab",
                                "sorafenib",
                                "lenvatinib",
                                "regorafenib",
                                "cabozantinib",
                                "ramucirumab",
                                "nivolumab",
                                "nivolumab plus ipilimumab",
                                "pembrolizumab",
                                "any other approved or experimental first line and/or second line therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with Child-Pugh A or B (at time of enrollment) as defined by the parameters contained in the Child-Pugh Calculator. Subjects with Child-Pugh score of B8-B9 may be included if they have:",
            "criterions": [
                {
                    "exact_snippets": "Patients with Child-Pugh A or B (at time of enrollment)",
                    "criterion": "Child-Pugh class",
                    "requirements": [
                        {
                            "requirement_type": "class",
                            "expected_value": [
                                "A",
                                "B"
                            ]
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "at time of enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with Child-Pugh score of B8-B9 may be included",
                    "criterion": "Child-Pugh score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 8,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 9,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Radiologic diagnosis of HCC as per the AASLD guidelines OR",
            "criterions": [
                {
                    "exact_snippets": "Radiologic diagnosis of HCC as per the AASLD guidelines",
                    "criterion": "radiologic diagnosis of hepatocellular carcinoma (HCC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "HCC as per the AASLD guidelines"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is ≥ 20 mm with either non-peripheral portal washout or an enhancing capsule OR",
            "criterions": [
                {
                    "exact_snippets": "Is ≥ 20 mm",
                    "criterion": "lesion size",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 20,
                                "unit": "mm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "non-peripheral portal washout",
                    "criterion": "lesion imaging feature: portal washout",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "non-peripheral"
                        }
                    ]
                },
                {
                    "exact_snippets": "enhancing capsule",
                    "criterion": "lesion imaging feature: enhancing capsule",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients of childbearing potential and their partners and male patients must agree to use adequate contraception during the period of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Female patients of childbearing potential ... must agree to use adequate contraception during the period of study treatment.",
                    "criterion": "contraception use (female patients of childbearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the period of study treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "male patients must agree to use adequate contraception during the period of study treatment.",
                    "criterion": "contraception use (male patients)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the period of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Biopsy-proven HCC that is locally advanced or metastatic OR",
            "criterions": [
                {
                    "exact_snippets": "Biopsy-proven HCC",
                    "criterion": "hepatocellular carcinoma (HCC) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "biopsy-proven"
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced or metastatic",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Albumin ≥ 2.8 mg/l AND",
            "criterions": [
                {
                    "exact_snippets": "Albumin ≥ 2.8 mg/l",
                    "criterion": "albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.8,
                                "unit": "mg/l"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least one target lesion that has not previously received any local therapy, such as surgery, radiation therapy, hepatic arterial embolization, transarterial chemoembolization (TACE), hepatic arterial infusion, radio-frequency ablation, percutaneous ethanol injection or cryoablation, unless it has subsequently progressed by 20% or more according to RECIST v 1.1 and mRECIST for HCC.",
            "criterions": [
                {
                    "exact_snippets": "At least one target lesion",
                    "criterion": "target lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "has not previously received any local therapy, such as surgery, radiation therapy, hepatic arterial embolization, transarterial chemoembolization (TACE), hepatic arterial infusion, radio-frequency ablation, percutaneous ethanol injection or cryoablation",
                    "criterion": "target lesion prior local therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior local therapy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "unless it has subsequently progressed by 20% or more according to RECIST v 1.1 and mRECIST for HCC",
                    "criterion": "target lesion progression after local therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": {
                                "operator": ">=",
                                "value": 20,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients receiving other anticancer treatments.",
            "criterions": [
                {
                    "exact_snippets": "Patients receiving other anticancer treatments",
                    "criterion": "other anticancer treatments",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients that do not agree to be followed according to the study protocol.",
            "criterions": [
                {
                    "exact_snippets": "do not agree to be followed according to the study protocol",
                    "criterion": "agreement to be followed according to the study protocol",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients receiving calcium channel blockers and any agent blocking L-type of T-type Voltage Gated Calcium Channels, e.g., amlodipine, nifedipine, ethosuximide, ascorbic acid (vitamin C), etc. unless their medical treatment is modified to exclude calcium channel blockers prior to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Patients receiving calcium channel blockers ... unless their medical treatment is modified to exclude calcium channel blockers prior to enrollment.",
                    "criterion": "calcium channel blocker use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "any agent blocking L-type of T-type Voltage Gated Calcium Channels, e.g., amlodipine, nifedipine, ethosuximide, ascorbic acid (vitamin C), etc. unless their medical treatment is modified to exclude ... prior to enrollment.",
                    "criterion": "L-type or T-type voltage gated calcium channel blocker use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known leptomeningeal disease. (Previously treated, asymptomatic central nervous system (CNS) metastases are eligible).",
            "criterions": [
                {
                    "exact_snippets": "Known leptomeningeal disease.",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Previously treated, asymptomatic central nervous system (CNS) metastases are eligible",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "previously treated"
                        },
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "asymptomatic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with the TheraBionic Device.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with the TheraBionic Device",
                    "criterion": "prior treatment with the TheraBionic Device",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or breastfeeding women.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant ... women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding women",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Fibrolamellar HCC or combined hepatocellular-cholangiocarcinoma (cHCC-CC).",
            "criterions": [
                {
                    "exact_snippets": "Fibrolamellar HCC",
                    "criterion": "fibrolamellar hepatocellular carcinoma (HCC)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "combined hepatocellular-cholangiocarcinoma (cHCC-CC)",
                    "criterion": "combined hepatocellular-cholangiocarcinoma (cHCC-CC)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with another active malignancy within the past one year except for treated cervical cancer in situ, treated in situ carcinoma of the bladder or treated non-melanoma carcinoma of the skin, low-risk prostate cancer not requiring active treatment, treated T1/T2 glottic cancer, treated stage 0 or stage I breast cancer not requiring adjuvant therapy or treated non-invasive bladder cancer.",
            "criterions": [
                {
                    "exact_snippets": "Patients with another active malignancy within the past one year",
                    "criterion": "active malignancy (other than index cancer)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for treated cervical cancer in situ, treated in situ carcinoma of the bladder or treated non-melanoma carcinoma of the skin, low-risk prostate cancer not requiring active treatment, treated T1/T2 glottic cancer, treated stage 0 or stage I breast cancer not requiring adjuvant therapy or treated non-invasive bladder cancer",
                    "criterion": "history of specific prior malignancies",
                    "requirements": [
                        {
                            "requirement_type": "allowed types",
                            "expected_value": [
                                "treated cervical cancer in situ",
                                "treated in situ carcinoma of the bladder",
                                "treated non-melanoma carcinoma of the skin",
                                "low-risk prostate cancer not requiring active treatment",
                                "treated T1/T2 glottic cancer",
                                "treated stage 0 or stage I breast cancer not requiring adjuvant therapy",
                                "treated non-invasive bladder cancer"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with curative treatment options available, including surgery or radiofrequency ablation, as assessed by their physician.",
            "criterions": [
                {
                    "exact_snippets": "Patients with curative treatment options available, including surgery or radiofrequency ablation",
                    "criterion": "curative treatment options",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment_types",
                            "expected_value": [
                                "surgery",
                                "radiofrequency ablation"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "as assessed by their physician",
                    "criterion": "physician assessment of curative treatment options",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": "physician"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with any of the following within the 12 months prior to registration: uncontrolled/unstable angina, myocardial infarction, coronary artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, including transient ischemic attack, or pulmonary embolism.",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled/unstable angina ... within the 12 months prior to registration",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled or unstable"
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction ... within the 12 months prior to registration",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "coronary artery bypass graft ... within the 12 months prior to registration",
                    "criterion": "coronary artery bypass graft",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic congestive heart failure ... within the 12 months prior to registration",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cerebrovascular accident, including transient ischemic attack ... within the 12 months prior to registration",
                    "criterion": "cerebrovascular accident or transient ischemic attack",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "pulmonary embolism ... within the 12 months prior to registration",
                    "criterion": "pulmonary embolism",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}